公司資料
Exicure 股價、新聞與催化劑
- 股票代碼:
- XCUR
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
1.15 USD (-11.54%)
收盤價
最後更新: 2026年8月21日
19.8M USD
市值
股價為何變動
As of Aug 21, 2026, XCUR closed down 11.5% at $1.15. No new same-company headline was identified in the current news window.
公司概覽
Early-Stage Biopharmaceutical Operations
Exicure is rebuilding a research and development business following the acquisition of GPCR Therapeutics USA. The company has limited liquidity and is simultaneously evaluating financing and strategic alternatives.
Stem-Cell Mobilization Program
Its lead development program is being evaluated for improving stem-cell mobilization in multiple myeloma and sickle cell disease and for supporting cell and gene therapy procedures. The source disclosure does not provide a named candidate or development timetable.
未來催化劑
- Exicure is largely a legacy and closeout story, so the catalysts are any strategic or asset-resolution update rather than a live development milestone. The market is focused on what remains.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。